Brhlikova Petra, Babar Zaheer-Ud-Din, Pollock Allyson M
Population Health Sciences Institute, Newcastle University, Baddiley-Clark Building, Newcastle upon TyneNE2 4AX, England.
College of Pharmacy, Qatar University, Doha, Qatar.
Bull World Health Organ. 2025 Jan 1;103(1):37-42. doi: 10.2471/BLT.24.291512. Epub 2024 Oct 29.
Access to essential medicines is still suboptimal in many countries. Recent studies examining the registration of medicines at the country level show that a considerable proportion of essential medicines do not have any corresponding products registered for use at the country level and therefore cannot be available at all times. Conversely, many non-essential medicines are registered by regulatory authorities for local markets, potentially facilitating inappropriate drug use and antimicrobial resistance. Addressing this public health gap requires linking the data on national drug registers with national essential medicines lists. Achieving this linkage will necessitate the development of common data variables and standards for both drug registers and essential medicines lists. This linkage would provide medicines regulators and health policy-makers with information on the gaps in the registration of essential medicines and allow them to take steps to prioritize registration of these medicines. This approach would improve availability of essential medicines for public health priorities and prevent over-registration of unnecessary medicines.
在许多国家，基本药物的可及性仍然不尽人意。近期在国家层面审查药品注册情况的研究表明，相当一部分基本药物在国家层面没有任何相应的注册产品可供使用，因此无法随时获取。相反，许多非基本药物却被监管机构注册用于当地市场，这可能助长不恰当的药物使用和抗菌药物耐药性。解决这一公共卫生差距需要将国家药品注册数据与国家基本药物清单相联系。实现这种联系将需要为药品注册和基本药物清单制定通用的数据变量和标准。这种联系将为药品监管机构和卫生政策制定者提供有关基本药物注册差距的信息，并使他们能够采取措施优先对这些药物进行注册。这种方法将改善基本药物用于公共卫生重点领域的可及性，并防止对不必要药物的过度注册。
